The investigational monoclonal antibody barzolvolimab significantly improved provocation test outcomes and reduced symptoms ...

Urticaria commonly known as hives is a skin condition characterised by red itchy welts or bumps that can appear anywhere on the body Try these home remedies that can help you manage this condition ...

Simmons deemed her to be “a healthy 59-year-old female who has a medical history notable for seasonal allergies and urticaria ...

Dr. Joshua Simmons, an Army colonel and physician to the vice president, also said the VP has a history of seasonal allergies and urticaria, or hives, which he described as “transient.” ...

Dupilumab (Dupixent), a fully human monoclonal antibody that targets the interleukin (IL)-4 and IL-13 pathways, is currently ...

Incyte Corp.’s mention of would-be “backup molecules” could bode well for findings yet to roll out with Mas-related G protein-coupled receptor X2 antagonist INCB-000262 in chronic spontaneous ...

Take chronic spontaneous urticaria (CSU), for example. When you have CSU, it means dealing with hives that last for six weeks or more. The condition can be life-altering for people who struggle ...

The US Food and Drug Administration (FDA) has accepted a resubmission of the supplemental Biologics License Application for ...

Dr. Joshua Simmons, an Army colonel and physician to the vice president, also said the vice president has a history of seasonal allergies and urticaria, or hives, which he described as ...

Jasper Therapeutics, Inc.'s Briquilimab shows promise in treating chronic urticaria and asthma, with potential market approval by 2027, offering significant revenue opportunities in large ...

The FDA has accepted for review the resubmitted sBLA for dupilumab for the treatment of chronic spontaneous urticaria.

Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for review the resubmission of the supplemental Biologics License ...